ArticleMarine drugs2026
Phaseolorin J Alleviates Cellular Inflammation and Oxidative Stress by Inhibiting NLRP3 Inflammasome Expression via the Nrf2/HO-1 Pathway.
Article in Marine drugs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Research Progress on Marine Active Substances in Improving Atherosclerosis.Marine drugs · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Phaseolorin J (TT-55), a chromone compound isolated and purified from the fermentation products of Phomopsis asparagi DHS-48, is an endophytic fungus obtained from mangrove forests. Preliminary experimental studies have revealed its potent antioxidant and anti-inflammatory activities, though its mechanism of action remains unclear. In this study, we aimed to investigate the molecular mechanisms underlying the antioxidant and anti-inflammatory effects of TT-55, following initial evidence of its potency, by employing an LPS-induced RAW264.7 macrophage model in vitro. The results revealed that in the LPS-induced inflammatory model of RAW264.7 cells, the TT-55 dose dependently inhibited the expression of LPS-induced inflammatory cytokines (TNF-α, IL-18, IL-1β, IL-6) and the production of oxidative stress markers (reactive oxygen species, SOD, MDA). Following combined treatment with the Nrf2 pathway inhibitor ML385 and TT-55, the inhibitory effects of TT-55 on inflammatory cytokines and oxidative stress markers were reversed by ML385. Meanwhile, ML385 also attenuated the ability of TT-55 to suppress LPS-induced upregulation of NLRP3 inflammasome-related genes. In conclusion, TT-55 may exert its antioxidant and anti-inflammatory effects by activating the Nrf2/HO-1 signaling pathway and suppressing the upregulation of NLRP3 inflammasome-related genes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.